en · de · es · pt
liraglutide-notes.peptides7250.com › Topic › Dual Incretin Receptor Agonism — Research Overview

Dual Incretin Receptor Agonism — Research Overview

By Editorial Desk · published 2025-10-24 · last reviewed 2025-11-29 · Topic

This is a working overview of GLP-1 receptor, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2025-11-29. Anything still debated is marked as such rather than presented as settled.

Dual Incretin Receptor Agonism

Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.

The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.

Tirzepatide 分子背景与靶点

脂肪酸侧链的存在使该肽与血浆白蛋白结合能力增强,从而延长循环半衰期,支持每周一次给药的用药间隔。白蛋白结合同时改变组织分布特征,减慢肾脏清除速度。该设计思路在多种长效肽类药物中被反复采用,属于既定的药代动力学策略。

该化合物的名称与结构由国际非专利名称体系统一维持,不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。

当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体,而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录,可作为分析检测和质量研究的参照。

Tirzepatide at a glance

PropertyValueNotes
Molecular classSynthetic peptideDual GIP/GLP-1 receptor agonist
Amino acid count39Contains non-natural residues
ModificationC20 fatty diacidAttached via linker; promotes albumin binding
Half-lifeApproximately 5 daysSupports once-weekly dosing
Primary routeSubcutaneous injectionNot for intravenous use

Molecular Background and Receptor Pharmacology

Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.

The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.

After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.

Related pages on this site

Analytical Characterisation and Storage Practice

Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.

Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.

Long-term storage of lyophilised peptide powder is generally at minus twenty degrees Celsius or colder, with desiccant and protection from light. Short-term storage at two to eight degrees Celsius is common during active use. In solution, stability depends strongly on pH, concentration, and the presence of preservatives, and hydrolysis or aggregation can develop over weeks. Published stability data specific to this molecule are limited, so recommended conditions for research material are usually extrapolated from general peptide handling practice rather than from a dedicated study.

Analytical Characterization and Stability

Stability depends strongly on physical form. The dry powder is generally regarded as stable for extended periods when held at or below minus twenty degrees Celsius in a sealed, desiccated container. In solution, degradation pathways include deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation. Reaction rates for these pathways rise with temperature. Repeated freezing and thawing of solutions promotes aggregation, and light exposure can accelerate some oxidative changes. Buffer composition and pH influence which pathway dominates at a given temperature.

Regulatory and quality discussions place the peptide within established guidance for synthetic peptides and biologics. Forced degradation studies, in which samples are exposed to heat, acid, base, peroxide, and light, identify likely degradation products and validate the selectivity of analytical methods. Reference standards allow comparison across laboratories and production batches. Purity specifications reported in the literature usually combine chromatographic purity with mass confirmation. Which impurity thresholds are meaningful for long-term behavior is still debated, and no single universal specification has been adopted across all jurisdictions.

Peptide Structure and Receptor Pharmacology

Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.

The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.

Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.

Further detail

directionality The end-to-end orientation of a linear strand or sequence of a nucleic acid polymer or a polypeptide. The nomenclature used to indicate nucleic acid directionality is based on the chemical convention of identifying individual carbon atoms in the ribose or deoxyribose sugars of nucleotides, specifically the 5' carbon and 3' carbon of the pentose ring. The sequence of nucleotides in a polymeric chain may be read or interpreted in the 5'-to-3' direction (i.e. starting from the terminal nucleotide in which the 5' carbon is not connected to another nucleotide, and proceeding to the other terminal nucleotide, in which the 3' carbon is not connected to another nucleotide) or in the opposite 3'-to-5' direction. Most types of nucleic acid synthesis, including DNA replication and transcription, build chains of nucleotides exclusively in the 5'-to-3' direction, because the polymerases involved can only catalyze the addition of free nucleotides to the open 3'-end of the previous nucleotide in the chain. Because of this, the convention when writing any nucleic acid sequence is to present it in the 5'-to-3' direction from left to right. In double-stranded nucleic acids, the two paired strands must be oriented in opposite directions in order to base-pair with each other.

== Bibliography == Barrow, Logie; Bullock, Ian (1996). Democratic Ideas and the British Labour Movement, 1880–1914. Cambridge University Press. ISBN 9780521560429. Benn, Tony (1980). Arguments for Socialism. Penguin. ISBN 9780140054897. Dorrien, Gary (2019). Social Democracy in the Making: The Political and Religious Roots of European Socialism. Yale University Press. ISBN 9780300236026. Draper, Hal (1966). "The Two Souls of Socialism". New Politics. 5 (1): 57–84. Harrington, Michael (1989). Socialism: Past and Future. Arcade Publishing. ISBN 9781559700009. Hatterlsey, Roy (1987). Choose Freedom: The Future of Democratic Socialism. Penguin. ISBN 0140104941. Doherty, James C.; Lamb, Peter (2006). Historical Dictionary of Socialism (2nd ed.). The Scarecrow Press. ISBN 9780810855601. Miliband, Ralph (1994). Socialism for a Sceptical Age. London, United Kingdom: Polity Press. ISBN 9780745614274. Reisman, Reidsman, ed. (1996). Democratic Socialism in Britain: Classic Texts in Economic and Political Thought, 1825–1952. Chatto and Pickering. ISBN 9781851962853. Thomas, Norman (1953). Democratic Socialism: A New Appraisal. League for Industrial Democracy. ASIN B0007ECO76. Tomlinson, Jim (1997). Democratic Socialism and Economic Policy: The Attlee Years, 1945–1951. Cambridge University Press. ISBN 0521550955.

Dermatology Neurosurgery Ophthalmology Oral and maxillofacial surgery Orthopedic surgery Otorhinolaryngology Podiatric surgery – do not undergo medical school training, but rather separate training in podiatry school Urology

Opioids can produce strong feelings of euphoria and are frequently used recreationally. Traditionally associated with illicit opioids such as heroin, prescription opioids are misused recreationally. Drug misuse and non-medical use include the use of drugs for reasons or at doses other than prescribed. Opioid misuse can also include providing medications to persons for whom it was not prescribed. Such diversion may be treated as crimes, punishable by imprisonment in many countries. In 2014, almost 2 million Americans abused or were dependent on prescription opioids.

Sources: en.wikipedia.org

Background from the literature

== Organizations == Macedonian Scientific Institute, an institution in Sofia, Bulgaria Marketing Science Institute, a nonprofit learning institution in Cambridge, Massachusetts, US Media Sport Investment, the international fund of investors that ran Sport Club Corinthians Paulista Millennium Science Initiative, an international program bringing technology to developing nations Ministry of Science and Innovation (New Zealand) Minority-serving institution, in US higher education MSI Reproductive Choices, an international non-governmental organisation providing contraception and safe abortion services, with a global HQ in London, UK Museum of Science and Industry (Chicago), US Science and Industry Museum, in Manchester, England University of Minnesota Supercomputing Institute Italian Social Movement (Movimento Sociale Italiano), a defunct post-fascist party

==== As a later synthesis by monks ==== Hajime Nakamura has argued that we should search the Sutta Nipata for the earliest form of dependent origination since it is the most ancient source. According to Nakamura, "the main framework of later theories of Dependent Origination" can be reconstructed from the Sutta Nipata as follows: avidya, tanha, upadana, bhava, jaramarana. Lambert Schmitthausen has also argued that the twelve-fold list is a synthesis from three previous lists, arguing that the three lifetimes-interpretation is an unintended consequence of this synthesis.

ImmTACs exert their activity through T cell redirection, a mechanism of action used by several other bi-specific biologics such as the Bi-specific T-cell engagers (BiTEs). After administration of the drug the picomolar affinity TCR portion of the ImmTAC binds to the cancerous or virally infected cell through specific recognition of target HLA-peptide complexes on their cell surface. This picomolar affinity binding results in the diseased cells becoming coated in CD3 co-receptor specific scFv antibody fragments that constitute the ImmTAC effector function. Any Cytotoxic T cell that subsequently comes into direct physical contact with the ImmTAC coated diseased cell is redirected to kill it, regardless of the specificity of its native TCR. This redirected killing does not require binding of any co-stimulatory molecules and is effected through the targeted release of perforin and granzyme from the redirected T cell that induces the targeted disease cell to die through an apoptosis mediated mechanism. However, the danger of activating a wide variety of nonspecific cytotoxic T cell clones via anti-CD3 scFv exists, leading to their proliferation and widespread autoimmunity.

Sources: en.wikipedia.org

Frequently asked questions

What receptors does tirzepatide target?

It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.

How is tirzepatide administered?

It is given as a subcutaneous injection. Its long half-life supports weekly dosing.

Is tirzepatide a natural peptide?

No, it is synthetic. It contains non-natural amino acids and a fatty acid modification.

Tirzepatide 属于哪一类分子?

它属于合成修饰肽,同时激动 GIP 与 GLP-1 两种肠促胰素受体。这类分子通常被称为双重肠促胰素受体激动剂,与选择性 GLP-1 激动剂在靶点范围上不同。

Network